Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
FISH is the biggest sticking point in Brexit talks now as Boris Johnson wants control over its waters back while the EU wants access to the fishing waters.
However, Britain and the EU have made good progress in talks on a last-minute trade deal.
The UK left the EU in January but the two sides are trying to clinch a deal that would govern nearly a trillion dollars in annual trade before informal membership - known as the transition period - ends on Dec. 31.
"We're in intense negotiations with the EU - we've made real progress," Trade Secretary Liz Truss said. "We're making good progress on the negotiations."
"But if the EU aren't prepared to do a deal that allows the UK to retain its sovereignty, then we will go to Australia style terms, and I think that's perfectly reasonable."
The chief negotiators of Britain and the European Union, Michel Barnier and David Frost, meet on Friday for intensive negotiations.
After some progress on competition guarantees including state aid rules, the hardest issue remains fish:
Ireland's foreign minister said he believed Britain and the EU could reach a trade deal now the talks were back on track, but added the issues of fair competition and fisheries hampering an accord were "still very much there".
Asked if there would be a deal, Britain's junior finance minister Stephen Barclay said he hoped there would be but fishing was a key sticking point.
"(The) deal needs to reflect that fact that we're leaving the EU, we will regain control of our fisheries," he told Sky.
At a briefing with diplomats in Brussels on Wednesday(21), Barnier said he was only worried about fish, one person who participated in the closed-door meeting said.
"Fish is now the thing to tackle. The other elements seem doable, more or less," the diplomat said.
While fishing alone contributed just 0.03 per cent of British economic output in 2019, it is an emotive subject as many Brexit supporters see it as a symbol of the regained sovereignty that leaving the EU should bring. Combined with fish and shellfish processing, then the sector makes up 0.1 per cent of UK GDP.
For French fishermen, British waters are crucial and being locked out would cause trouble for French president Emmanuel Macron.
Meanwhile, Britain and Japan formally signed a trade agreement on Friday(23), marking the UK's first big post-Brexit deal on trade, as it continues to struggle to agree on a deal with its closest trading partners in the EU.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.